Distributed Bio, a BroadOak portfolio company, provided Charles River Laboratories’ clients access to Distributed Bio’s antibody libraries and integrated antibody optimization technologies.
Distributed Bio is a provider of antibody discovery, engineering, informatics tools, and services for the life sciences research and drug discovery markets.
The full press release is below.
Charles River and Distributed Bio Enter Exclusive Partnership to Create an Integrated Antibody Discovery and Development Platform
New partnership allows Charles River’s clients access to Distributed Bio’s antibody discovery platforms
WILMINGTON, Mass. & SAN FRANCISCO–(BUSINESS WIRE)–Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an exclusive partnership with Distributed Bio, Inc., a leader in the computational design and optimization of antibody discovery platforms.
This partnership will grant Charles River’s clients access to Distributed Bio’s antibody libraries and integrated antibody optimization technologies. Distributed Bio’s libraries are computationally optimized for both sequence diversity and engineering fitness through the analysis of thousands of human antibody repertoires and all known monoclonal therapeutics in clinical trials. A combination of Distributed Bio’s antibody libraries and Charles River’s extensive drug development expertise will create a unique end-to-end platform for therapeutic antibody discovery and development.
Advanced Human Antibody Libraries
Distributed Bio’s computational immunoengineering platform provides libraries that can generate more than 5,000 unique hits against every antigen tested. This platform improves the chance of successful hit finding, reduces optimization requirements, and expedites the discovery process to as little as three to four months. Distributed Bio’s computational immunology expertise also enables optimization of existing client antibodies generated through more traditional platforms, such as hybridoma or traditional phage display.
With a focus on speed and design, this partnership will help increase the probability of success for delivering high-quality antibody candidates.
“Distributed Bio’s technology, coupled with Charles River’s deep scientific strength in drug discovery and early-stage development, ensures that our portfolio is truly next generation. This combination provides our clients with Distributed Bio’s ability to discover new antibodies, then proceed seamlessly from hit to clinical candidate faster than before.” – Birgit Girshick, Corporate Executive Vice President of Discovery and Safety Assessment at Charles River.
“Charles River is the premier, early-stage contract research organization with a global reach and a track record of excellence. Leveraging our revolutionary antibody discovery and engineering platforms and Charles River’s downstream capabilities will deliver a comprehensive research experience from idea to clinic. We are about to release the third generation of our discovery platform and sought a partner that had both the scale to match our growth and the agility to realize the value of our antibody platforms as fast as possible.” – Jake Glanville, Ph.D., Founding Partner and Chief Science Officer at Distributed Bio.